EU/3/18/2054

About

On 31 July 2018, orphan designation (EU/3/18/2054) was granted by the European Commission to Mallinckrodt Specialty Pharmaceuticals Ireland Limited, Ireland, for tetracosactide for the treatment of Duchenne muscular dystrophy.

Key facts

Active substance
Tetracosactide
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of decision
31/07/2018
Outcome
Positive
Orphan decision number
EU/3/18/2054

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Mallinckrodt Pharmaceuticals Ireland Limited
College Business & Technology Park
Cruiserath, Blanchardstown
Dublin 15, Ireland
Tel. +41 41 726 3045
E-mail: hermann.schultze@mnk.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating